Scarica l'app Stockscreener
1.48
0.68%
0.01
Dopo l'orario di chiusura:
1.49
0.01
+0.68%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PYXS Giù?
Forum
Previsione
Precedente Chiudi:
$1.47
Aprire:
$1.43
Volume 24 ore:
194.65K
Relative Volume:
0.27
Capitalizzazione di mercato:
$92.99M
Reddito:
$13.86M
Utile/perdita netta:
$-79.62M
Rapporto P/E:
-1.1531
EPS:
-1.2835
Flusso di cassa netto:
$-63.51M
1 W Prestazione:
+6.47%
1M Prestazione:
+0.68%
6M Prestazione:
-34.22%
1 anno Prestazione:
+45.10%
Intervallo 1D:
$1.40
$1.495
Intervallo di 1 settimana:
$1.26
$1.55
Portata 52W:
$0.8332
$5.55
Pyxis Oncology Inc Stock (PYXS) Company Profile
Nome
Pyxis Oncology Inc
Settore
Industria
Telefono
(617) 221-9059
Indirizzo
321 HARRISON AVENUE, BOSTON
Compare PYXS vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.48 | 92.99M | 13.86M | -79.62M | -63.51M | -1.2835 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-03 | Ripresa | Stifel | Buy |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2024-11-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | Iniziato | Stephens | Overweight |
| 2024-08-08 | Iniziato | Stifel | Buy |
| 2024-05-07 | Ripresa | Jefferies | Buy |
| 2024-02-09 | Iniziato | BTIG Research | Buy |
| 2024-01-23 | Iniziato | Leerink Partners | Outperform |
| 2023-09-05 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-11-02 | Iniziato | BofA Securities | Neutral |
| 2021-11-02 | Iniziato | Credit Suisse | Outperform |
| 2021-11-02 | Iniziato | Jefferies | Buy |
Mostra tutto
Pyxis Oncology Inc Borsa (PYXS) Ultime notizie
Wall Street Zen Downgrades Pyxis Oncology (NASDAQ:PYXS) to Sell - marketbeat.com
PYXS Technical Analysis & Stock Price Forecast - Intellectia AI
PYXS SEC FilingsPyxis Oncology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
PYXS Earnings History & Surprises | EPS & Revenue Results | PYXIS ONCOLOGY INC (NASDAQ:PYXS) - ChartMill
Pyxis Oncology Inc. (PYXS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Pyxis Oncology (PYXS) Receives a Rating Update from a Top Analyst - The Globe and Mail
Pyxis Oncology (NASDAQ:PYXS) Stock Rating Upgraded by Wall Street Zen - marketbeat.com
PYXS Stock Price, Quote & Chart | PYXIS ONCOLOGY INC (NASDAQ:PYXS) - ChartMill
Stock Report: Can Pyxis Oncology Inc expand its profit marginsDividend Hike & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Q1 EPS Estimates for Pyxis Oncology Raised by HC Wainwright - marketbeat.com
Pyxis Oncology director Humphrey sells $15917 in shares By Investing.com - Investing.com Australia
Pyxis Oncology (PYXS) director receives 45,867 stock options at $1.36 strike - Stock Titan
Pyxis Oncology director Humphrey sells $15917 in shares - Investing.com UK
Pyxis Oncology (PYXS) grants director Jakob Dupont 45,867 stock options - stocktitan.net
Executive at Pyxis Oncology (PYXS) receives new option and RSU equity grants - stocktitan.net
Pyxis Oncology (PYXS) director receives grant of 45,867 stock options - Stock Titan
[Form 4] Pyxis Oncology, Inc. Insider Trading Activity - Stock Titan
Director at Pyxis Oncology (PYXS) receives grant of 45,867 stock options - Stock Titan
Pyxis Oncology (NASDAQ:PYXS) Director Rachel Humphrey Sells 13,896 Shares - MarketBeat
Pyxis Oncology (PYXS) director sells 15,496 shares under 10b5-1 plan - Stock Titan
FY2029 EPS Estimates for Pyxis Oncology Lifted by Analyst - MarketBeat
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $5 - Moomoo
A Quick Look at Today's Ratings for Pyxis Oncology(PYXS.US), With a Forecast Between $5 to $7 - Moomoo
Stifel Nicolaus Lowers Pyxis Oncology (NASDAQ:PYXS) Price Target to $8.00 - marketbeat.com
Stifel cuts Pyxis Oncology stock price target on financing assumptions By Investing.com - Investing.com India
Pyxis Oncology (NASDAQ:PYXS) Given Buy Rating at HC Wainwright - MarketBeat
Guggenheim reiterates Buy on Pyxis Oncology stock ahead of trial data By Investing.com - Investing.com South Africa
Guggenheim reiterates Buy on Pyxis Oncology stock ahead of trial data - Investing.com India
H.C. Wainwright reiterates Buy on Pyxis Oncology stock, $7 target By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Buy on Pyxis Oncology stock, $7 target - Investing.com
Pyxis Oncology (PYXS) Rating Reiterated as Buy by HC Wainwright & Co. | PYXS Stock News - GuruFocus
RBC Capital Initiates Pyxis Oncology(PYXS.US) With Buy Rating, Announces Target Price $5 - Moomoo
Stifel cuts Pyxis Oncology stock price target on financing assumptions - Investing.com
Pyxis Oncology Reports 2025 Financial Results, Advances MICVO Cancer Trials, and Announces New Leadership - Minichart
Pyxis Oncology Reports Q4 Results, Advances MICVO Program - TipRanks
William Blair reiterates Pyxis Oncology stock rating on trial pace By Investing.com - ca.investing.com
William Blair reiterates Pyxis Oncology stock rating on trial pace - Investing.com UK
Jefferies raises Pyxis Oncology stock price target on drug data By Investing.com - Investing.com Australia
Jefferies raises Pyxis Oncology stock price target on drug data - Investing.com
MicuRx Pharmaceuticals: Advancing Novel ADC Therapy MICVO for Difficult-to-Treat Head and Neck Cancer – Pipeline, Strategy, and Risks Overview - Minichart
Pyxis Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Pyxis Oncology (NASDAQ:PYXS) Posts Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Pyxis Oncology 10-K: Revenue $13.9M; Net loss $(79.6)M - TradingView
Pyxis Oncology (PYXS) highlights MICVO ADC progress in head and neck cancer - Stock Titan
Pyxis Oncology : March 2026 Corporate Deck (ae13e6) - MarketScreener
Pyxis Oncology (NASDAQ: PYXS) details 2025 results and MICVO head & neck cancer data - Stock Titan
Pyxis Oncology 2025 net loss widens on higher R&D spend - TradingView
BRIEF-Pyxis Oncology FY Net Income USD -79.621 Million - TradingView
Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewswire
Pyxis Oncology Inc Azioni (PYXS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):